Dr. Richard Sonnenblick

AI at the Inflection Point

by

Note from Editor: This post is adapted from Dr. Rich Sonnenblick’s presentation at the 30th European Biopharma Project, Program, & Portfolio Management Conference in Basel. In his presentation, Dr. Sonnenblick dispelled the hype surrounding AI and agents, while sharing concrete examples of how drug development teams are saving hundreds of hours, de-risking their clinical pipelines,…

Manage Risks, But Don’t Eliminate Them

by

When companies value stability over innovation, some risks increase: they risk slowly losing market share and fading into the background of their industry. So what do we do? The solution lies in the understanding that effective R&D governance cannot, and should not, distill projects into a single number. Here are five ways to assess and communicate risk in your portfolio.